| avelumab based treatment | Immune checkpoint association |
| avelumab alone | avelumab plus pegylated liposomal doxorubicin | nivolumab plus ipilimumab |
Comparator:
vs pegylated liposomal doxorubicin; vs nivolumab alone;
Risk of bias:
low;
some concerns;
high;
NA;